The report on the Nerve Repair and Regeneration market gives an in-depth statistical analysis to examine the fastest growing sectors in the market while speculating the demand and supply, consumption power, spending capacity and distribution channel globally. The report identifies the overall growth in the import and export and derives the future trends that the industry might witness. The study also applies primary and secondary research methods to assess the annual and financial performance of the top vendors and insights from market leaders. The researcher also discusses the recent trends and developments including joint ventures, collaborations, investments, product launches and acquisitions and mergers constitute a substantial part of the research on the Nerve Repair and Regeneration market for the forecast period from 2020 to 2027. The report will empower companies to understand the opportunities, adapt to their consumer demands, needs, and concentrate on their best end-users. The global Nerve Repair and Regeneration Market will be worth USD 11.62 Billion by 2027, according to a current analysis by Emergen Research.
Key Highlights
From The Report
In 2019, Medtronic launched the Intellis platform for the
management of certain types of chronic intractable pain. The platform was
designed to overcome limitations with current spinal cord stimulation (SCS)
systems, such as battery performance, and power the Evolve workflow. It can
track patients 24/7 and help in monitoring chronic pain.
The Neurostimulation and Neuromodulation Devices segment
held the largest market share of 59.4% in 2019. The increasing incidence of
spinal injuries is expected to increase the demand for spinal cord stimulation
devices and drive the growth of the Neurostimulation and Neuromodulation
Devices.
Stem Cell Therapy is forecasted to grow with the fastest
CAGR of 9.7% over the forecast period. Increasing brain and spinal cord injury,
neurodegeneration, frailty syndrome, and heart diseases have increased the
adoption of stem cell therapies.
The Asia Pacific region is expected to be the
fastest-growing region over the forecast period due to the supportive
government initiatives to improve the healthcare infrastructure and increase
healthcare budgetary allocation.
Key
participants include Abbott Laboratories, Medtronic, Plc, Boston
Scientific Corporation, BAXTER INTERNATIONAL, INC., LIVANOVA, PLC., AXOGEN,
INC., Stryker Corporation, Cyberonics, Inc., INTEGRA LIFESCIENCES, and SOTERIX
MEDICAL, INC., among others.
Regional
scope- North America; Europe; Asia Pacific; Central & South
America; MEA
Product
Outlook (Revenue, USD Billion; 2017-2027)
Neurostimulation and Neuromodulation Devices (Sacral Nerve,
Spinal Cord, Vagus Nerve, Gastric Electric, and Deep Brain Stimulation Devices)
Biomaterial
Surgery
Outlook (Revenue, USD Billion; 2017-2027)
Stem Cell Therapy
Direct Nerve Repair
Nerve Grafting
Neurostimulation and Neuromodulation Surgeries
No comments:
Post a Comment